PURPOSE: In patients with soft-tissue sarcoma (STS), the early assessment of treatment responses is important. Using positron emission tomography/computed tomography (PET/CT) with [(18)F]fluorodeoxyglucose (FDG), we determined whether changes in tumor FDG uptake predict histopathologic treatment responses in high-grade STS after the initial cycle of neoadjuvant chemotherapy. EXPERIMENTAL DESIGN: From February 2006 to March 2008, 50 patients with resectable high-grade STS scheduled for neoadjuvant therapy and subsequent tumor resection were enrolled prospectively. FDG-PET/CT before (baseline), after the first cycle (early follow-up), and after completion of neoadjuvant therapy (late follow-up) was done. Tumor FDG uptake and changes were measured by standardized uptake values. Histopathologic examination of the resected specimen provided an assessment of treatment response. Patients with > or = 95% pathologic necrosis were classified as treatment responders. FDG-PET/CT results were compared with histopathologic findings. RESULTS: At early follow-up, FDG uptake decreased significantly more in 8 (16%) responders than in the 42 (84%) nonresponders (-55% versus -23%; P = 0.002). All responders and 14 of 42 nonresponders had a > or = 35% reduction in standardized uptake value between baseline and early follow-up. Using a > or = 35% reduction in FDG uptake as early metabolic response threshold resulted in a sensitivity and specificity of FDG-PET for histopathologic response of 100% and 67%, respectively. Applying a higher threshold at late follow-up improved specificity but not sensitivity. CT had no value at response prediction. CONCLUSION: A 35% reduction in tumor FDG uptake at early follow-up is a sensitive predictor of histopathologic tumor response. Early treatment decisions such as discontinuation of chemotherapy in nonresponding patients could be based on FDG-PET criteria.
PURPOSE: In patients with soft-tissue sarcoma (STS), the early assessment of treatment responses is important. Using positron emission tomography/computed tomography (PET/CT) with [(18)F]fluorodeoxyglucose (FDG), we determined whether changes in tumorFDG uptake predict histopathologic treatment responses in high-grade STS after the initial cycle of neoadjuvant chemotherapy. EXPERIMENTAL DESIGN: From February 2006 to March 2008, 50 patients with resectable high-grade STS scheduled for neoadjuvant therapy and subsequent tumor resection were enrolled prospectively. FDG-PET/CT before (baseline), after the first cycle (early follow-up), and after completion of neoadjuvant therapy (late follow-up) was done. TumorFDG uptake and changes were measured by standardized uptake values. Histopathologic examination of the resected specimen provided an assessment of treatment response. Patients with > or = 95% pathologic necrosis were classified as treatment responders. FDG-PET/CT results were compared with histopathologic findings. RESULTS: At early follow-up, FDG uptake decreased significantly more in 8 (16%) responders than in the 42 (84%) nonresponders (-55% versus -23%; P = 0.002). All responders and 14 of 42 nonresponders had a > or = 35% reduction in standardized uptake value between baseline and early follow-up. Using a > or = 35% reduction in FDG uptake as early metabolic response threshold resulted in a sensitivity and specificity of FDG-PET for histopathologic response of 100% and 67%, respectively. Applying a higher threshold at late follow-up improved specificity but not sensitivity. CT had no value at response prediction. CONCLUSION: A 35% reduction in tumorFDG uptake at early follow-up is a sensitive predictor of histopathologic tumor response. Early treatment decisions such as discontinuation of chemotherapy in nonresponding patients could be based on FDG-PET criteria.
Authors: Christoph Pöttgen; Sabine Levegrün; Dirk Theegarten; Simone Marnitz; Sara Grehl; Roman Pink; Wilfried Eberhardt; Georgios Stamatis; Thomas Gauler; Gerald Antoch; Andreas Bockisch; Martin Stuschke Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Corneline J Hoekstra; Sigrid G Stroobants; Egbert F Smit; Johan Vansteenkiste; Harm van Tinteren; Pieter E Postmus; Richard P Golding; Bonne Biesma; Frans J H M Schramel; Nico van Zandwijk; Adriaan A Lammertsma; Otto S Hoekstra Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: Benjamin S Halpern; Magnus Dahlbom; Martin A Auerbach; Christiaan Schiepers; Barbara J Fueger; Wolfgang A Weber; Daniel H S Silverman; Osman Ratib; Johannes Czernin Journal: J Nucl Med Date: 2005-04 Impact factor: 10.057
Authors: Giovanni L Ceresoli; Arturo Chiti; Paolo A Zucali; Marcello Rodari; Romano F Lutman; Silvia Salamina; Matteo Incarbone; Marco Alloisio; Armando Santoro Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: William G Kraybill; Jonathon Harris; Ira J Spiro; David S Ettinger; Thomas F DeLaney; Ronald H Blum; David R Lucas; David C Harmon; G Douglas Letson; Burton Eisenberg Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544
Authors: Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong Journal: Skeletal Radiol Date: 2011-02-06 Impact factor: 2.199
Authors: Ashok J Theruvath; Florian Siedek; Anne M Muehe; Jordi Garcia-Diaz; Julian Kirchner; Ole Martin; Michael P Link; Sheri Spunt; Allison Pribnow; Jarrett Rosenberg; Ken Herrmann; Sergios Gatidis; Jürgen F Schäfer; Michael Moseley; Lale Umutlu; Heike E Daldrup-Link Journal: Radiology Date: 2020-05-05 Impact factor: 11.105
Authors: Janet F Eary; Ernest U Conrad; Janet O'Sullivan; Douglas S Hawkins; Scott M Schuetze; Finbarr O'Sullivan Journal: J Bone Joint Surg Am Date: 2014-01-15 Impact factor: 5.284
Authors: Paul E Kinahan; Robert K Doot; Michelle Wanner-Roybal; Luc M Bidaut; Samuel G Armato; Charles R Meyer; Geoffrey McLennan Journal: Transl Oncol Date: 2009-12 Impact factor: 4.243
Authors: Matthias R Benz; Johannes Czernin; William D Tap; Jeffrey J Eckardt; Leanne L Seeger; Martin S Allen-Auerbach; Sarah M Dry; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber Journal: Sarcoma Date: 2010-04-18